Dura Pharmaceuticals, Inc. v. Scandipharm, Inc.

713 A.2d 925, 1998 Del. Ch. LEXIS 24, 1998 WL 83076
CourtCourt of Chancery of Delaware
DecidedFebruary 20, 1998
DocketCivil Action 16149
StatusPublished
Cited by18 cases

This text of 713 A.2d 925 (Dura Pharmaceuticals, Inc. v. Scandipharm, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dura Pharmaceuticals, Inc. v. Scandipharm, Inc., 713 A.2d 925, 1998 Del. Ch. LEXIS 24, 1998 WL 83076 (Del. Ct. App. 1998).

Opinion

OPINION

LAMB, Vice Chancellor.

I. INTRODUCTION

Before the Court is the defendant’s motion to dismiss or stay this action in favor of an *927 action filed by it in the Circuit Court of Shelby County, Alabama (the “Alabama Action”). Defendant argues that the Alabama Action is the first filed action, involves the same parties and issues and is pending in a court capable of doing prompt and complete justice between the parties. Thus, it suggests, Delaware authorities, beginning with McWane Cast Iron Pipe Corp. v. McDowell-Wellman Eng’g Corp., Del Supr., 263 A.2d 281 (1970), require that this action be dismissed or stayed in favor of the Alabama Action.

Plaintiff responds that the McWane comity analysis should not apply because, inter alia, the actions were filed so closely in time that neither should be accorded “first filed” status. Alternatively, the plaintiff opposes the motion on the ground that the other factors normally examined in relation to a motion to dismiss for forum non conveniens weigh in favor of litigating in Delaware rather than Alabama.

The motion will be granted because the factors enumerated in McWane are present here and, in the absence of special circumstances not present here, while Delaware might be a more convenient forum than Alabama for the conduct of this litigation, the relative conveniences of the parties cannot outweigh or overcome the “strong preference for the litigation of a dispute between named parties in [the] forum in which suit was first instituted.” E.I. Du Pont De Nemours & Co. v. Cigna Property & Cas. Co., Del.Ch., C.A No. 12386, Allen, C., 1992 WL 171427 (July 17,1992) slip op. at 9.

II. FACTS

Plaintiff, Dura Pharmaceuticals, Inc. (“Dura”), is a Delaware corporation having its principal place of business in San Diego, California. Dura manufactures and sells pharmaceutical products, including products to treat allergies, asthma and other respiratory conditions.

Defendant, Seandipharm, Inc. (“Scandip-harm”), is a Delaware corporation having its principal place of business in Birmingham, Alabama. Seandipharm is a pharmaceutical distributor and sells, among other things, products to treat cystic fibrosis.

Both this action and the Alabama action arise out of the negotiation and performance of an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into on October 20, 1997 between Seandipharm, Dura and Scandi Acquisition Corp. (“Acquisition Sub”), a wholly owned subsidiary of Dura formed for the purpose of merging with and into Seandipharm. The contacts and negotiations leading up to the merger took place in Texas, California and Alabama and involved advisors in California, Pennsylvania and Maryland. As a part of this process, on October 7-8, 1997, representatives of the parties met in Alabama for a drafting session and due diligence review. The Merger Agreement was executed in counterparts by Dura and Acquisition Sub in San Diego and by Seandipharm in Alabama. On November 29, 1997, Dura purported unilaterally to terminate the Merger Agreement, allegedly as a result of its having learned certain information giving rise to a right to do so in accordance with the terms of the Merger Agreement.

The Merger Agreement provides that it is to be governed by and construed and enforced in accordance with Delaware law. It also contains a provision by which the parties agree that “any action or proceeding arising out of or relating to” the Merger Agreement “may be heard and determined in any Delaware state or federal court” and by which each party “irrevocably waives, to the fullest extent it may effectively do so, the defense of an inconvenient forum to the maintenance of such action or proceeding.” (Merger Agreement, § 10.06)

On Friday, January 16,1998, Seandipharm filed suit against Dura in the Circuit Court of Shelby County, situated in Columbiana, Alabama. Columbiana is approximately 40 miles from Birmingham and is the seat of the county in which Seandipharm maintains its executive offices. The complaint naming Dura and Acquisition Sub as defendants, alleges that Dura wrongfully terminated the Merger Agreement and seeks specific performance and damages. Seandipharm notified Dura on January 16th of the filing of the *928 Alabama Action, although actual service of the complaint was not accomplished until the following week.

Reacting to the filing of the Alabama Action, Dura attempted to commence this action on Sunday, January 18th, by depositing a complaint in the Register in Chancery’s night box. This was ineffective, and Dura refiled the complaint on Tuesday, January 20th, the next business day. In its complaint, Dura seeks: (i) a declaration that it properly terminated the Merger Agreement, (ii) specific performance of the termination provisions of the Merger Agreement, and (iii) damages based on tort theories of fraud, equitable fraud and negligent misrepresentation. The tort claims all revolve around the same disclosure issue that is alleged to give rise to the right to terminate the contract.

In opposition to the pending motion, Dura presented, in addition to its brief, the Affidavit of James W. Newman, Senior Vice President, Finance and Administration and Chief Financial Officer of Dura. Paragraphs 30-41 of the Newman Affidavit contains factual assertions regarding the location of witnesses and the relative ease of access to proof in Delaware and Alabama.

III. DISCUSSION

It is well established that this Court may, in the exercise of its discretion, dismiss or stay an action pending before it in favor of an action pending in another jurisdiction. McWane, 263 A.2d at 283. It is equally well settled that this Court’s discretion “should be exercised freely in favor of the stay when there is a prior action pending elsewhere, in a court capable of doing prompt and complete justice, involving the same parties and the same issues,” and that “as a general rule, litigation should be confined to the forum in which it is first commenced, and that a defendant should not be permitted to defeat the plaintiffs choice of forum in a pending suit by commencing litigation involving the same cause of action in another jurisdiction of its own choosing.” Id. These principles are “impelled by considerations of comity and the necessities of an orderly and efficient administration of justice.” Id.

[Thus], there is avoided the wasteful duplication of time, effort and expense that occurs when judges, lawyers, parties' and witnesses are simultaneously engaged in the adjudication of the same cause of action in two courts. Also to be avoided is the possibility of inconsistent and conflicting rulings and judgments and an unseemly race by each party to trial and judgment in the forum of its choice.

Id. As discussed, infra, I hold that McWane requires the stay or dismissal of this action.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Logan v. Loco Florida, LLC
Superior Court of Delaware, 2024
Bright Data, Inc. v. Meta Platforms
Superior Court of Delaware, 2023
In re: CVS Opioid Insurance Litigation
Superior Court of Delaware, 2022
Kennedy v. Barboza
Superior Court of Delaware, 2016
Lima Delta Company
Superior Court of Delaware, 2016
Willis v. PCA Pain Center of Virginia, Inc.
Court of Chancery of Delaware, 2014
Lisa, S.A. v. Mayorga
993 A.2d 1042 (Supreme Court of Delaware, 2010)
In Re the Topps Co. Shareholders Litigation
924 A.2d 951 (Court of Chancery of Delaware, 2007)
Biondi v. Scrushy
820 A.2d 1148 (Court of Chancery of Delaware, 2003)
Caravetta v. McKesson HBOC, Inc.
846 A.2d 240 (Superior Court of Delaware, 2000)
Derdiger v. Tallman
773 A.2d 1005 (Court of Chancery of Delaware, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
713 A.2d 925, 1998 Del. Ch. LEXIS 24, 1998 WL 83076, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dura-pharmaceuticals-inc-v-scandipharm-inc-delch-1998.